{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:17:12Z","timestamp":1771841832299,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["R\/136413-11-1"],"award-info":[{"award-number":["R\/136413-11-1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.vph.2016.05.010","type":"journal-article","created":{"date-parts":[[2016,6,5]],"date-time":"2016-06-05T22:15:19Z","timestamp":1465164919000},"page":"25-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors"],"prefix":"10.1016","volume":"84","author":[{"given":"Mark R.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2016.05.010_bb0005","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1365-2141.2000.02208.x","article-title":"The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity","volume":"110","author":"Storey","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.vph.2016.05.010_bb0010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.05.010_bb0015","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2016.05.010_bb0020","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.05.010_bb0025","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2016.05.010_bb0030","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jama.2011.1332","article-title":"High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI","volume":"306","author":"Parodi","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2016.05.010_bb0035","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11936-011-0157-2","article-title":"Optimal management of antiplatelet therapy and proton pump inhibition following percutaneous coronary intervention","volume":"14","author":"Thomas","year":"2011","journal-title":"Curr. Treat Options Cardio Med."},{"key":"10.1016\/j.vph.2016.05.010_bb0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-12-386930-2.00006-9","article-title":"Genetics of response to antiplatelet therapy","volume":"124","author":"Thomas","year":"2014","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.vph.2016.05.010_bb0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.thromres.2015.03.011","article-title":"Determinants of subacute response to clopidogrel: relative impact of CYP2C19 genotype and PGE1\/adenylate cyclase signalling","volume":"136","author":"Hurst","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.vph.2016.05.010_bb0050","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2016.05.010_bb0055","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.05.010_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2016.01.003","article-title":"Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor","author":"Siller-Matula","year":"2016","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.vph.2016.05.010_bb0065","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1160\/TH09-11-0770","article-title":"Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function","volume":"103","author":"Judge","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2016.05.010_bb0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","article-title":"Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention","volume":"35","author":"Aradi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.05.010_bb0075","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2015.01.047","article-title":"Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention","volume":"65","author":"Kazi","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2016.05.010_bb0080","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1160\/TH14-02-0119","article-title":"Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events","volume":"112","author":"Alexopoulos","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2016.05.010_bb0085","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient outcomes) PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2016.05.010_bb0090","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.05.010_bb0095","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2016.05.010_bb0100","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/eurheartj\/ehv137","article-title":"More transparency for a therapeutic window in platelet P2Y12 inhibition?","volume":"36","author":"Storey","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2016.05.010_bb0105","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.vph.2016.05.010_bb0110","author":"Roffi","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2016.05.010_bb0115","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","article-title":"Platelet inhibition with ticagrelor 60mg versus 90mg twice daily in the PEGASUS-TIMI 54 trial","volume":"67","author":"Storey","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2016.05.010_bb0120","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1537189116300325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1537189116300325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T11:46:41Z","timestamp":1498304801000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189116300325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":24,"alternative-id":["S1537189116300325"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2016.05.010","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.vph.2016.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.vph.2016.01.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}